


CANNABINOIDS CLINICAL RESEARCH



CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS

Pioneers of groundbreaking research for alternative
next-level medicine





The following presentation contains proprietary information about [CBIH](#), a public company listed on the OTC Markets. The information includes, among other matters, financial information, marketing concepts and strategies, marketing plans, and designs for trade and trademarks. By reading this executive summary, you agree all the information is confidential and the property of [CBIH](#). You agree you will not disclose the information to any other person without the written authorization of [CBIH](#). You further agree you will not use the information for any purpose except the evaluation of the business plan for possible investment in the business venture it describes.

[These financial estimates are based upon management's opinion as to reasonable results assuming the projects materialize. There can be no assurance that any of these results will be obtained.](#)

WELCOME TO CBIH

Working in medical cannabis research for 15 years **and NOW prepared to take it to the next level... with you,** health professionals, and the patients that need a new and better option in their recovery journey



In all, PubMed.gov now cites over 42,500 scientific publish studies on cannabis, developed by Health Institutions, Labs, Scientific Groups, Government Entities, various countries, Universities, and Cannabinoids Researchers Around The World. And the studies keep increasing...

CANNABINOIDS

Cannabinoids are the main chemical compounds of the Cannabis plant. These include THC, CBD, CBC, CBN, and CBG.

GOOD NEWS

There are several cancers (breast cancer, prostate cancer, leukemia, skin cancer, pheochromocytoma, and lymphoma), that in experimental situations can be killed by cannabinoids.

OUR PROJECT

Research of the **effect of cannabinoids in the treatment of medical conditions**, including Cancer, COVID, opioid addiction, and chronic pain, among others.





CBG

Anti-inflammatory, neuroprotective, and neuromodulatory, antibacterial, antiviral, anti-proliferative, anti-nausea and mental health regulator.

CBC

Bone stimulant, anti-fungal, anti-bacterial, anti-inflammatory, analgesic

CBN

Immunomodulatory, anti-inflammatory, antibiotic, somniferous, analgesic, antioxidant

THCV

Appetite regulation, obesity management, type 2 diabetes management, anticonvulsant, metabolic syndrome treatment

THC

Analgesic, anti-inflammatory, anxiolytic, anti-emetic, antitumoral antioxidant, decreases intraocular pressure

Delta-8-THC:

Relaxation, euphoria, pain relief, anxiolytic, analgesic, antiemetic

CBD

Anti-inflammatory, neuroprotective, immunomodulatory, antioxidant, anticonvulsant, anxiolytic, antitumoral

CBGA

Antiviral, anti-inflammatory, antitumoral, sedative, may support heart health and metabolic disorders

What's the advised temperature for vaping cannabinoids?



TEMP °C	CANNABINOIDS	TREATMENTS	TEMP °F	+COMPUNDS	TREATMENTS
BP 220 °C 220	Cannabichromene CBC Active State	• Anti-proliferative • Anti-bacterial • Bone Stimulant • Anti-inflammatory • Analgesic	BP 428 °F 428	+ pulegone + quercetin = <i>Smoke & Vapour</i>	Sedative, Anti-pyretic AChE Inhibitor, and Insecticide. Anti-oxidant, Anti-neoplastic, Anti-viral, Anti-mutagenic, and a CBD synergistic compound
BP < 220 °C 220	Tetrahydrocannabivarin THCV Active State (C ₃)	• Euphoriant, Anti-THC • Analgesic • Anti-diabetic • Anorectic • Bone Stimulant	BP < 428 °F 428	+ α-terpineol = <i>Smoke & Vapour</i> = Ready to consume	Anti-anxiety, Anti-oxidant, Anti-microbial, Sedative, Anti-protozoal, Anti-biotic, and Anti-malarial. <i>(Reduce toxins by consuming)</i>
BP - BENZENE 205	Hydrocarbons SMOKE Benzene, and more	*** WARNING *** Toxic Vapours 200 °C 392 °F Harmful toxins begin: Reduce Toxins in Cannabis	BP - BENZENE 401	+ terpinen-4-ol = <i>Smoke & Vapour</i> + borneol	Anti-biotic, AChE Inhibitor, and may increase memory. Traditional Chinese Medicine, used as a "moxa."
BP - THEORY 195	Cannabielsoin CBE Active State	CBE increases with prolonged exposure to heat, oxygen & light. Likely to contain cannabinoids other than CBE. Showing the Maximum Medical Temp.	BP - THEORY 383	+ linalool = <i>Nighttime Meds</i> = <i>Club Favourite</i>	Powerful Sedative, reduces Anxiety, Anti-stress, Anti-depressant, Anxiolytic, Immune Potentiator, and a CBD synergistic compound
BP 185 °C 185	Cannabinol CBN Active State	CBN increases with prolonged exposure to heat, oxygen & light. • Anti-spasmodic • Anti-insomnia • Analgesic	BP 365 °F 365	+ cannflavin A = <i>Nighttime Meds</i> = <i>MORRM Favourite</i>	Prostaglandin E2 Inhibitor, Cyclooxygenase Inhibitor, and Lipoxygenase Inhibitor <i>(pending device temp. error)</i>
BP 177 °C 175	Tetrahydrocannabinol THC Active Δ8 (C ₃)	The Δ8 cannabinoid mode lead to Hebrew University's HU-210. • 10% as psychoactive Δ9 • Neuroprotective • Anti-emetic	BP 351 °F 347	+ eucalyptol + limonene + p-cymene + apigenin	Anti-viral, Anti-biotic, Dietary Anti-cancer tool. Anti-biotic, Anti-candidal. Opioid receptor Antagonist.
160° - 180 °C 165	Cannabidiol CBD Active State	Most conditions listed EXCLUDING the following: • Anti-insomnia • Anti-fungal • Anti-anorectic	320° - 356 °F 329	+ β-myrcene = <i>Daytime Meds</i> + Δ-3-carene	Anti-biotic, and Anti-mutagenic. Analgesic, and Anti-inflammatory with slight Sedative effects.
BP 157 °C 155	Tetrahydrocannabinol THC Active Δ9 (C ₃)	• Anti-inflammatory • Anti-anorectic • Anti-emetic • Anti-proliferative • Anti-oxidant	BP 315 °F 311	+ α-myrcene = <i>Daytime Meds</i> = <i>3rd Med Vapour</i>	With CBD treats MRSA, Anti-inflammatory, Bone Stimulant, Anti-biotic, Bronchodilator, Cytotoxic, and may increase memory.
100° - 145 °C 140	Cannabichromene CBCA Acidic State	1) Req. 60 mins in the oven* 2) When eaten <i>unheated</i> : • Anti-bacterial • Anti-fungal • Not full elucidated	212° - 293 °F 284	+ β-sitosterol = <i>2nd Med Vapour</i> ** CBC conversion	5-α-reductase inhibitor, Anti-inflammatory and Chronic Edema treatment <i>(Avoid 1-Shareal feeding) Pregnant Increases CBD, and CBE</i>
80° - 135 °C 130	Cannabidiol CBDA Acidic State	1) Req. 60 mins in the oven* 2) When eaten <i>unheated</i> : • Anti-proliferative • Anti-inflammatory • Not full elucidated	176° - 275 °F 266	+ β-caryophyllene = <i>1st Med Vapour</i> ** CBC conversion	Cytoprotective, Neuroprotective, Analgesic, Anti-malarial, Anxiolytic, and Anti-inflammatory. <i>(Increases CBD and CBE)</i>
60° - 125 °C 120	Tetrahydrocannabinol THCA Acidic State	1) Req. 60 mins in the oven... 2) When eaten <i>unheated</i> : • Anti-inflammatory • Anti-epileptic • Anti-proliferative	146° - 251 °F 248	Cannabigerol + CBG Acidic State	<i>(Conversion occurs while curing)</i> • Anti-inflammatory • Analgesic, Anti-bacterial • Anti-fungal, Bone Stimulant • Anti-proliferative

I LOVE TO HOMEGROW

COMPETITORS ...

Pfizer Bets On Medical Cannabis With \$6.7 Billion Acquisition

“Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for \$100 per share, in cash, for a total equity value of approximately \$6.7 billion. The acquisition was completed by way of a merger in accordance with Delaware law and, as a result of the acquisition, Arena became a wholly-owned subsidiary of Pfizer.”

Friday, March 11, 2022

Arena Pharmaceuticals is a biotech company with one pipeline dedicated to cannabinoid-type therapeutics. The core of its cannabis operation consists of Olorinab (APD371), an investigational, oral, full agonist of the cannabinoid type 2 receptor (CB2), which aims to treat patients with diseases affecting the stomach and intestine.



MEDICINE FINDS ANSWERS IN NATURE

A Little History of Medicine

In 1928 Dr. Alexander Fleming returned from a holiday **to find mold growing on a Petri dish of Staphylococcus bacteria**. He noticed the mold seemed to be preventing the bacteria around it from growing. He soon identified that **the mold produced a self-defense** chemical that could kill bacteria. **He named the substance penicillin.**



THE ENDOCANNABINOID SYSTEM

Naturally occurring compounds


- Anandamide and 2-AG
- The “Keys”

Molecules attach to receptors

- The “Locks”
- CB1 receptor in many areas of the brain
- CB2 receptor mainly in the immune system

The result is inhibiting nerve action

- Part of the braking system in the brain
- Multiple roles in the immune system



We are a global team of innovators



Scientific Experts

Ph.D. in Science, Professional biologists, and Cannabis experts

We understand the plant

Health Professionals

Oncologists, MDs, Psychologists, Radiologists.

We understand the human body

Legal and Operations

Lawyers, Accountants, Marketing experts, and Executives.

We understand results

YOU

Investor, Patient

With a Powerful Role in Our Future

Our team manifesto... Better health moves the human **spirit**, heals the **body**, and keeps the **mind** focused on the art of living well

YOU


Investor
of
the
future



Brian Cuban
Director



John Jones
Treasurer and
Director



Barry J Miller
Attorney at Law
- Securities



Stephen
Khoury Corp.
Attorney



Dr. Jose Torres
Torres National
Medical Director



Dante Picazo
CEO



Jorge Verar
CPA - Certified
Public Accountant



Victor Mokuolu, CPA
PCAOB



Dr. Ugochi Ekeocha
Master of Health
Care Administration



Jennifer
Salguero
Ph.D. in Sciences



Katerin Osuna R.
Master -
Communication



Dr. Ibeth Corrales
Doctorate in
Dental Surgery



Dr. Stephanie
Hartmann
Doctor, MD



Nancy Duarte
Ph. D. in Biology



Ana Maldonado
Pharmaceutical
chemist



Rosangel Andrades
Doctor, MD



Dr Yesiree
Baptista
Doctor, MD



Nancy Rodrigues Das Fontes
Pharmaceutical chemist



Viviana Camacho
Comptroller - Magister
Scientiarum in
Administration



Mariana Sardi
Administrator -
Project Coordinator



Tivisay Diaz
BA in
Administration



Bethania Molina
Administrative
Assistant





WHY DO WE DO IT?

... Cancer, Multiple sclerosis, Alzheimer,
Epilepsy, Chronic pain...

To create a better quality of life!



*At least 71.8% and as many
as 80% of **overdose deaths**
involve **opioids**.*

In 2023, **1,958,310 new cancer cases** and **609,820 cancer deaths** are projected to occur in the United States.

Behind a scar, there is a human being with the desire to smile again

Cannabinoids and Cancer Treatment: Cannabinoids are the main chemical compounds of the Cannabis plant. These include THC, CBD, and CBG. These compounds have shown to be effective in helping cancer patients reduce the side effects of chemotherapy (nausea, vomiting, loss of appetite, weight loss, pain)





The global CBD oil and CBD consumer health market is expected to grow from \$39.54 billion in 2022 to \$49.72 billion in 2023 at a compound annual growth rate (CAGR) of 25.75%.

Cannabidiol (CBD) Market to Reach **USD 55,791.3 Million by 2028** | With a CAGR of 47.49%

BIOAVAILABILITY

The extent or fraction of a substance or **drug that becomes completely available** to its intended biological destination(s)

Drug pharmacology

When administered orally, the drug faces different barriers.

First, it passes through the acidic gastric pH
Then it reaches the intestine (it can be metabolized by enzymes) and is absorbed into the capillaries which then drain into the liver.
In the liver, the drug is metabolized and transformed (Hepatic First Pass Effect)

**AS A RESULT, THE
BIOAVAILABILITY DECREASES**



How can we improve the drug bioavailability?


Cannabis extracts are highly lipophilic molecules and can have immiscibility in some presentations (edible infusions, beverages, creams, and other infused products), therefore, there is a need for a suitable emulsification method.

Nanoemulsions work as small droplets that provide a higher degree of clarity, stability, and low viscosity.


A study showed that CBD nanoemulsions greatly enhanced the absorption of CBD and improved its bioavailability.



Standard Oil
10% or less absorption



Liposomal Microemulsion
100-1000 Nanometer
20% Absorption



Nano-Sized Microemulsion
25 Nanometer (Avg)
50% Absorption Maximum Bioavailability



THE ANSWER IS Nanoemulsions

The tiny size of the nanoemulsion droplets and their ability to solubilize very hydrophobic drugs provide an **opportunity to dramatically increase the rate of drug dissolution** and thus the expected systemic bioavailability.



ARTIFICIAL INTELLIGENCE IN MEDICINE

Thanks to advances in computing and hardware, and the emergence of deep learning and artificial neural networks, **AI programs are becoming increasingly present in clinical practice.** These have been used for clinical and genomic diagnostics, chronic disease management, and sophisticated surgical robots.



How Artificial Intelligence is Revolutionizing Discovery, Manufacturing, and medicinal cannabis?

“AI will allow the scientific community to obtain in 1 year of research, what traditional methodologies would normally learn in 30 years”

IA programs are able to understand, adapt, react, and provide answers according to a specific context. **This would help to optimize the processes of scientific research** and formulation of new medical products.



These programs under the human supervision of a team of medical professionals, chemists, biologists, and engineers have the ability to **collect a large amount of information from many sources in seconds** and provide solutions/customized answers

It could track demand to improve production and could be used for content marketing and compliance with media laws. **And it could lower the cost of building brands** and reduce retail labor costs

Some News:

“AI suggested **40,000** new possible chemical weapons in just six hours”

“Artificial intelligence model finds potential drug molecules a **thousand times faster**”

“Artificial Intelligence (AI) Healthcare Market size was valued at USD 6.95 Billion in 2021 and is expected to grow at a **CAGR of 40.51 percent from 2022 to 2029**, reaching nearly USD 97.23 Billion.”

We are in a time when anyone can generate thousands of new molecules through AI, ***what matters is who does it to a significant ethical standard.***

ARTIFICIAL INTELLIGENCE

A program that can sense, reason, act, and adapt

MACHINE LEARNING

Algorithms whose performance improve as they are exposed to more data over time

DEEP LEARNING

Subset of machine learning in which multilayered neural networks learn from vast amounts of data

from the microscope to the market

2023
2028





The information gathered from our clinical research **will be used to either approve or deny the efficacy of our alternative OTC medications & treatments.**

Ultimately, we will ensure the scientific integrity of data and protect the rights, safety, and well-being of subjects enrolled in our mini-clinical trials.

Phase I

Establish human pharmacology & determine safe dose

Effectiveness of the drug is secondary

Phase II

Establish activity of the drug in a specific disease.

Confirm safe and tolerable dose

Establish nature and severity of toxicity

Possibly confirm pharmacology

Phase III

See if the new drug is better than the established therapy

See if drug is better than placebo

Establish activity of the drug

Reconfirm toxicity severity and nature in a larger population

Phase IV

Any rare or long-term effects of the drug can be observed in a much larger population of patients and over a much longer period of time

A large medical MRI machine with its gantry open, revealing the internal circular structure. A patient bed is positioned inside the gantry. The machine is light blue and white, with a warm glow emanating from the interior.

CBIH proposes a series of data medicinal research that falls outside of the traditional clinical trial setting, as our primary aim is not to seek FDA approval through a process that would probably take approximately 10 to 15 years and cost millions of dollars to produce FDA-approved drugs/medications.

In contrast, our proposed projects have as their cornerstone the understanding and knowledge of the palliative properties that medical cannabis offers to the human body and how it allows it to restore balance through the ubiquitous endocannabinoid system. **We expect that our formulations will allow us to understand the properties and impact of cannabinoids to restore homeostasis in the organism** and strengthen the immune system to improve symptoms, prevent consequences, optimize treatments, and provide a better quality of life for patients with chronic conditions, inflammatory diseases, and other pathologies.



Our collected data will also be utilized to create allegiances with pharmaceutical companies, medical institutions, or countries where our formulations can be utilized not as the last resource, but instead as a mainstream first-choice medication for those whom traditional medication has forgotten.

By 2026, the company **will have developed** capsules, ointments, syrups, oils, suppositories, orally disintegrating tablets, and many more nutraceuticals to aid in the treatment of different medical conditions.





Orthocann

Is an injectable nanoemulsion for intra-articular administration, combining 25 mg of Cannabichromene (CBC) and 45 mg of Cannabigerol (CBG), two phytocannabinoids with notable pharmacological properties.

NEUROCANN


Is a specialized formulation combining broad-spectrum Cannabidiol (CBD) oil derived from the cannabis plant, and prebiotics. The active ingredients include cannabinoids such as Cannabigerol (CBG), Cannabichromene (CBC), terpenes, and flavonoids..



VITAPANCREATIC CANCER

What is it?

VITAPANCREATICCANCER formulation targets advanced pancreatic cancer through a highly synergistic mechanism involving cannabinoids, terpenes, and flavonoids, all encapsulated within a nanoemulsion system for enhanced bioavailability and precision targeting of cancer cells.



VITABREASTCANCER



What is it?

is a cutting-edge formulation developed to treat breast cancer, especially in early stages, by integrating phytocannabinoids into advanced nanoplatform technology. This innovative approach is designed to precisely target breast cancer cells, inhibiting tumor growth by modulating key molecular pathways involved in cancer progression.



COVIDIOL SYRUP & COVIDIOL CAPSULES

What is it?

The proposal consists of syrup and capsules treatments applied at different stages of the disease caused by SARS- CoV-2 with the aim of modulating the patient's immune response using phytocannabinoid compounds.



CANNAWELL


What is it?

A signature formulation in drops to allow good absorption of CBD for the **treatment of seizures in case of epilepsy** and associated syndromes



CannaSutra

A signature formulation in soft gels to help with **erectile dysfunction**. Cannasutra is ideal to enhance the sex drive and libido, achieving the connection between sexual desire and reproductive man anatomy while increasing sexual stamina with added health and longevity benefits.



CannaValentine



CannaValentine provides relief from vaginal dryness and the annoyance and pain it can cause. As a libido enhancer, CannaValentine improves emotional well-being while boosting women's sexual desires naturally.



CANNANOMA

Chemotherapy Cream

This ointment is formulated to act as a topical **anticancer treatment** applied to the affected area in order to relieve the symptoms. CBD, CBG, CBC, and THC inhibit the VEGF protein and related enzymes of the cancer-causing cells.



DISTENDA

For Nighttime Recovery

What is it?

These oral disintegrating strips are ideal to obtain a **sedative effect and fight sleep apnea, insomnia, or other sleep disorders**. The rapid dissolution of the strips will allow a fast effect.



Distenda

For Nighttime Recovery

CBD ORAL DISINTEGRATING STRIPS

Ideal to obtain a sedative effect and fight sleep apnea, insomnia, or other sleep disorders.

SALES

2026

-

2029

Product	Price	Units per Year	2026		2027	%	2028	%	2029	%	TOTAL	
					50% Increase		20% Increase		15% Increase			
VITACANCER - SUBLINGUAL DROPS	\$ 99,00	15.000	\$ 1.485.000	26,68%	\$ 7.425.000	28,7%	\$ 14.850.000	27,6%	\$ 17.077.500	24,4%	\$ 40.837.500	26,3%
MELANOMA - OINTMENT	\$ 79,00	10.000	\$ 790.000	14,20%	\$ 3.950.000	15,3%	\$ 7.900.000	14,7%	\$ 9.085.000	13,0%	\$ 21.725.000	14,0%
COVID - SYRUP	\$ 15,00	10.000	\$ 150.000	2,70%	\$ 750.000	2,9%	\$ 1.500.000	2,8%	\$ 1.725.000	2,5%	\$ 4.125.000	2,7%
COVID - CAPSULES	\$ 12,00	10.000	\$ -	0,00%	\$ 120.000	0,5%	\$ 240.000	0,4%	\$ 276.000	0,4%	\$ 636.000	0,4%
CANNALGESIC - SOFTGEL	\$ 14,00	10.000	\$ 140.000	2,52%	\$ 700.000	2,7%	\$ 1.400.000	2,6%	\$ 1.610.000	2,3%	\$ 3.850.000	2,5%
PTSD - SYRUP	\$ 39,00	10.000	\$ -	0,00%	\$ 390.000	1,5%	\$ 780.000	1,4%	\$ 897.000	1,3%	\$ 2.067.000	1,3%
SHINGLES - ORAL AND TOPICAL TREATMENT (SOFTGEL AND CREAM)	\$ 69,00	10.000	\$ -	0,00%	\$ 690.000	2,7%	\$ 1.380.000	2,6%	\$ 1.587.000	2,3%	\$ 3.657.000	2,4%
ANXIDIOL - SUBLINGUAL DROPS	\$ 39,00	10.000	\$ -	0,00%	\$ 390.000	1,5%	\$ 780.000	1,4%	\$ 897.000	1,3%	\$ 2.067.000	1,3%
NEUROCAN/DEPRESSION - SOFTGEL	\$ 39,00	10.000	\$ -	0,00%	\$ 390.000	1,5%	\$ 780.000	1,4%	\$ 897.000	1,3%	\$ 2.067.000	1,3%
MULTIPLE SCLEROSIS- SUBLINGUAL DROPS	\$ 69,00	10.000	\$ -	0,00%	\$ 690.000	2,7%	\$ 1.380.000	2,6%	\$ 1.587.000	2,3%	\$ 3.657.000	2,4%
MENOPAUSE -SOFTGEL	\$ 40,00	10.000	\$ -	0,00%	\$ 400.000	1,5%	\$ 800.000	1,5%	\$ 920.000	1,3%	\$ 2.120.000	1,4%
35 PLUS/ PREGNANCY - SOFTGEL	\$ 40,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ 400.000	0,7%	\$ 460.000	0,7%	\$ 860.000	0,6%
CANNAVALENTINE - LUBRICANT GEL	\$ 39,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ 390.000	0,7%	\$ 448.500	0,6%	\$ 838.500	0,5%
CANNACOLAGEN - GUMMY	\$ 49,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ 490.000	0,9%	\$ 563.500	0,8%	\$ 1.053.500	0,7%
CANNADENT-TOOTHPASTE	\$ 5,99	10.000	\$ -	0,00%	\$ -	0,0%	\$ 59.900	0,1%	\$ 68.885	0,1%	\$ 128.785	0,1%
VITA BREAST CANCER - SOFTGEL	\$ 99,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ 990.000	1,8%	\$ 1.138.500	1,6%	\$ 2.128.500	1,4%
VITA PANCREATIC CANCER - SOFTGEL	\$ 99,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ 990.000	1,8%	\$ 1.138.500	1,6%	\$ 2.128.500	1,4%
ORTHOCANN-INJECTION	\$ 120,99	10.000	\$ -	0,00%	\$ -	0,0%	\$ 1.209.900	2,2%	\$ 1.391.385	2,0%	\$ 2.601.285	1,7%
EWING SARCOMA - SUBLINGUAL DROPS	\$ 99,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ 990.000	1,8%	\$ 1.138.500	1,6%	\$ 2.128.500	1,4%
ALZHEIMER - INTRANASAL NANOEMULSION	\$ 49,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ 490.000	0,9%	\$ 563.500	0,8%	\$ 1.053.500	0,7%
DIABETES - ORAL OIL-IN-WATER NANOEMULSION	\$ 59,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ -	0,0%	\$ 590.000	0,8%	\$ 590.000	0,4%
GLAUCOMA - LENS	\$ 79,00	10.000	\$ -	0,00%	\$ -	0,0%	\$ -	0,0%	\$ 790.000	1,1%	\$ 790.000	0,5%
CLINICAL TRIALS/ WELLNESS CENTER			\$ 2.000.000	35,94%	\$ 8.000.000	30,9%	\$ 12.000.000	22,3%	\$ 20.000.000	28,6%	\$ 42.000.000	27,1%
VITACOOKIES			\$ 1.000.000	17,97%	\$ 2.000.000	7,7%	\$ 4.000.000	7,4%	\$ 5.000.000	7,2%	\$ 12.000.000	7,7%
HEMPNOPIATE - IN DEVELOPMENT	\$ 49,00	10.000	\$ 490.000	8,81%	\$ 2.450.000	9,5%	\$ 4.900.000	9,1%	\$ 5.635.000	8,1%	\$ 13.475.000	8,7%
TOTAL SALES		225.000	\$ 5.565.000	100%	\$ 25.895.000	100,0%	\$ 53.799.800	100,0%	\$ 69.849.770	100,0%	\$ 155.109.570	100,0%
Cost of sales:			\$ 1.669.500	30,0%	\$ 7.250.600	28,0%	\$ 13.987.948	26,0%	\$ 16.763.945	24,0%	\$ 39.671.993	25,6%
Marketing/ White Label/ Partnerships			\$ 1.391.250	25,0%	\$ 4.661.100	18,0%	\$ 6.455.976	12,0%	\$ 6.984.977	10,0%	\$ 19.493.303	12,6%
Shipping			\$ 445.200	8,0%	\$ 1.812.650	7,0%	\$ 3.227.988	6,0%	\$ 3.492.489	5,0%	\$ 8.978.327	5,8%
Packaging/Labeling			\$ 417.375	7,5%	\$ 1.553.700	6,0%	\$ 2.689.990	5,0%	\$ 2.793.991	4,0%	\$ 7.455.056	4,8%
Maintenance / Equipment			\$ 11.130	0,2%	\$ 103.580	0,4%	\$ 268.999	0,5%	\$ 419.099	0,6%	\$ 802.808	0,5%
Payroll			\$ 1.780.000	32,0%	\$ 6.400.000	24,7%	\$ 10.880.000	20,2%	\$ 12.300.000	17,6%	\$ 31.360.000	20,2%
Rent / Clinic / Nutritional Products			\$ 120.000	2,2%	\$ 192.000	0,7%	\$ 240.000	0,4%	\$ 336.000	0,5%	\$ 888.000	0,6%
Software Expenses			\$ 30.000	0,5%	\$ 10.000	0,0%	\$ 10.000	0,0%	\$ 10.000	0,0%	\$ 60.000	0,0%
Accounting Fees			\$ 150.000	2,7%	\$ 150.000	0,6%	\$ 150.000	0,3%	\$ 150.000	0,2%	\$ 600.000	0,4%
Legal Fees / Securities Attorney			\$ 120.000	2,2%	\$ 120.000	0,5%	\$ 120.000	0,2%	\$ 120.000	0,2%	\$ 480.000	0,3%
Legal Fees / Patents			\$ 200.000	3,6%	\$ 200.000	0,8%		0,0%		0,0%		0,0%
Insurance			\$ 10.000	0,2%	\$ 12.000	0,0%	\$ 18.000	0,0%	\$ 25.000	0,0%	\$ 65.000	0,0%
Other Expenses/Travel			\$ 30.000	0,5%	\$ 70.000	0,3%	\$ 80.000	0,1%	\$ 90.000	0,1%	\$ 270.000	0,2%
OTC/Edgar/Pacific Stock Transfer			\$ 20.000	0,4%	\$ 20.000	0,1%	\$ 20.000	0,0%	\$ 20.000	0,0%	\$ 80.000	0,1%
4 years - Clinical Research			\$ 500.000	9%	\$ 500.000	1,9%	\$ 500.000	0,9%	\$ 500.000	0,7%	\$ 2.000.000	1,3%
Total Costs and expenses			\$ (6.894.455)	-124%	\$ (23.055.630)	-89,0%	\$ (38.648.901)	-71,8%	\$ (44.005.500)	-63,0%	\$ (112.604.486)	-72,6%
Net Revenues			\$ (1.329.455)	-23,9%	\$ 4.089.370	15,8%	\$ 16.050.899	29,8%	\$ 26.444.270	37,9%	\$ 45.255.085	29,2%
Other Income/Funding			\$ 1.250.000	22,5%	\$ 1.250.000	4,8%	\$ 900.000	1,7%	\$ 600.000	0,9%	\$ 4.000.000	
Total			\$ (79.455)		\$ 5.339.370		\$ 16.950.899		\$ 27.044.270		\$ 49.255.084	

	2026	%	2027 50% Increase	%	2028 20% Increase	%	2029 15% Increase	%	TOTAL	
EBITDA	\$ (79.455)	-1,4%	\$ 5.339.370	20,6%	\$ 16.950.899	31,5%	\$ 27.044.270	38,7%	\$ 49.255.084	31,8%
<u>5 Yrs Depreciation</u>	\$ 741.445	13,3%	\$ 1.341.445	5,2%	\$ 447.148	0,8%	\$ 447.148	0,6%	\$ 2.235.741	1,4%
EBITDA - Operating Income	\$ (820.900)	-14,8%	\$ 3.997.925	15,4%	\$ 16.503.751	30,7%	\$ 26.597.122	38,1%	\$ 47.098.798	30,4%
Pretax Income	\$ (820.900)	-14,8%	\$ 3.997.925	15,4%	\$ 16.503.751	30,7%	\$ 26.597.122	38,1%	\$ 46.277.899	29,8%
<u>30% Taxes</u>	\$ (246.270)	-4,4%	\$ 1.199.378	4,6%	\$ 4.951.125	9,2%	\$ 7.979.137	11,4%	\$ 13.883.370	9,0%
Note Discount Expenses	\$ (600.000)	-10,8%								
Net Income / (Loss)	\$ (1.667.169)	-30,0%	\$ 2.798.548	10,8%	\$ 11.552.626	21,5%	\$ 18.617.985	26,7%	\$ 31.301.989	20,2%

Year	shares	Revenue (\$)	Company Valuation (\$)	Price per Share (\$)	Investment Value (\$)	Profit (\$)	ROI (%)	Stonebridge Advisory Inc.- Independent Valuation
Sales Forecast – 2026	14.285.714,29	5.565.000	17.145.000	0,0125	178.571,43	168.571,43	1685,71%	2 Billion
Sales Forecast – 2027	14.285.714,29	25.895.000	90.675.000	0,0225	321.428,57	311.428,57	3114,29%	2 Billion
Sales Forecast – 2028	14.285.714,29	53.799.800	184.589.700	0,0425	607.142,86	597.142,86	5971,43%	2 Billion
Sales Forecast – 2029	14.285.714,29	69.849.770	234.418.155	0,0525	750.000,00	740.000,00	7400,00%	2 Billion
Year	shares	Revenue (\$)	Company Valuation (\$)	Price per Share (\$)	Investment Value (\$)	Profit (\$)	ROI (%)	Stonebridge Advisory Inc.- Independent Valuation
Sales Forecast – 2026	35.714.285,71	5.565.000	17.145.000	0,0125	446.428,57	421.428,57	1685,71%	2 Billion
Sales Forecast – 2027	35.714.285,71	25.895.000	90.675.000	0,0225	803.571,43	778.571,43	3114,29%	2 Billion
Sales Forecast – 2028	35.714.285,71	53.799.800	184.589.700	0,0425	1.517.857,14	1.492.857,14	5971,43%	2 Billion
Sales Forecast – 2029	35.714.285,71	69.849.770	234.418.155	0,0525	1.875.000,00	1.850.000,00	7400,00%	2 Billion

Convertible Bridge Note & Warrant

Up to \$2.5M Capital Financing (minimum investment: \$10,000)

- Three year convertible Note, **due Dec 31, 2028, bearing 7% Simple interest per annum**
- Converts into **Series common Stock** (target corporate or VC round)
- Warrant coverage of **15%** fixed rate for **first \$750,000, 10%** fixed rate **\$750,000 – \$1,000,000; 5%** fixed rate **thereafter**
- Automatic and voluntary conversion (at holder's option after one year) of principal & interest into common stock
- Conversion number of shares + number of value of shares + interest + warrant after three years

Company Valuation

- Attractive valuation for CBIH, an **innovative company focused on scientific research, therapeutic product development, and education** related to the medicinal use of cannabis.
- StoneBridge Valuation - 06/10/2024 (\$2 Billion)


Growth & Exit Strategy

- Achieve **\$78M in revenue, pre-tax profit of \$17M in FY 2028**
- Possible merger or acquisition by end of 2028 Pharmaceutical Company
- Possible exit strategy by 2028-2029
- Public company **trading on OTC Markets (Ticker: CBIH)**
- **15 trademarks registered with the USPTO**
- **150 educational videos** (cultivation, medicine, cosmetics, cooking)
- Legal declassification/reclassification of cannabis in the U.S.
- **10 patents already filed with the USPTO** (25 projected in total)
- **50 therapeutic formulations** with intellectual property protection
- 250 eBooks and audiobooks publicly available in 7 languages
- Initial **\$2.5 million funding** secured in 2026



We want patients to look
at *YOU* and *US* and say:

“BECAUSE OF YOU,
I DIDN'T GIVE UP!”



Join us if you desire a world with better health and a better future!

For more information, please contact us:

CBIH

ir@cbih.net

214-733-0868

